ES2182888T3 - Inhibidores de la sintesis de los acidos grasos como agentes antimicrobianos. - Google Patents

Inhibidores de la sintesis de los acidos grasos como agentes antimicrobianos.

Info

Publication number
ES2182888T3
ES2182888T3 ES95909239T ES95909239T ES2182888T3 ES 2182888 T3 ES2182888 T3 ES 2182888T3 ES 95909239 T ES95909239 T ES 95909239T ES 95909239 T ES95909239 T ES 95909239T ES 2182888 T3 ES2182888 T3 ES 2182888T3
Authority
ES
Spain
Prior art keywords
synthesis
fatty acids
cells
inhibitors
antimicrobial agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95909239T
Other languages
English (en)
Inventor
James D Dick
Francis P Kuhajda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Application granted granted Critical
Publication of ES2182888T3 publication Critical patent/ES2182888T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

LA SINTESIS DE ACIDOS GRASOS (FAS) VIENE SOBREEXPRESADA POR CIERTOS ORGANISMOS INFECCIOSOS, QUE SON RESISTENTES A LOS ANTIBIOTICOS DISPONIBLES DE FORMA MAS HABITUAL. POR EL CONTRARIO, SE IDENTIFICA UNA ESCASA EXPRESION DE FAS EN LOS TEJIDOS DE PACIENTES. LA INHIBICION DE SINTESIS DE ACIDOS GRASOS ES POR ELLO TOXICA DE FORMA SELECTIVA PARA LAS CELULAS INVASORAS, MIENTRAS QUE LAS CELULAS DEL PACIENTE CON UNA REDUCIDA ACTIVIDAD DE FAS SON RESISTENTES. ESTA INVENCION PROPORCIONA UN METODO PARA TRATAR PACIENTES SEPTICOS, EN LOS QUE LA SINTESIS DE ACIDOS GRASOS POR LAS CELULAS INVASORAS QUEDA INHIBIDA, CON EL RESULTADO DE UNA INTERRUPCION DEL PROCESO DE LA ENFERMEDAD.
ES95909239T 1994-01-24 1995-01-24 Inhibidores de la sintesis de los acidos grasos como agentes antimicrobianos. Expired - Lifetime ES2182888T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/188,421 US5614551A (en) 1994-01-24 1994-01-24 Inhibitors of fatty acid synthesis as antimicrobial agents

Publications (1)

Publication Number Publication Date
ES2182888T3 true ES2182888T3 (es) 2003-03-16

Family

ID=22693071

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95909239T Expired - Lifetime ES2182888T3 (es) 1994-01-24 1995-01-24 Inhibidores de la sintesis de los acidos grasos como agentes antimicrobianos.

Country Status (13)

Country Link
US (1) US5614551A (es)
EP (1) EP0738107B1 (es)
JP (1) JPH09508370A (es)
KR (1) KR100395601B1 (es)
AT (1) ATE223215T1 (es)
AU (1) AU703272B2 (es)
CA (1) CA2181031A1 (es)
DE (1) DE69528039T2 (es)
DK (1) DK0738107T3 (es)
ES (1) ES2182888T3 (es)
MX (1) MX9602934A (es)
PT (1) PT738107E (es)
WO (1) WO1995019706A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010881A (en) * 1996-02-20 2000-01-04 Smithkline Beecham Corporation RibG
US5859027A (en) * 1996-02-26 1999-01-12 Chektec Corporation Antimicrobial agent
US5910509A (en) * 1996-06-20 1999-06-08 Broedel; Sheldon E. Antimicrobial agent for agriculture
WO1998003661A2 (en) * 1996-07-19 1998-01-29 Arch Development Corporation Antimicrobial agents, diagnostic reagents, and vaccines based on unique apicomplexan parasite components
US5750496A (en) * 1996-08-12 1998-05-12 Utah State University Method of controlling cryptosporidium infectons using protease inhibitors
EP0956289A4 (en) * 1996-08-16 2004-10-13 Smithkline Beecham Corp NOVEL PROKARYOTA POLYNUCLEOTIDES AND POLYPEPTIDES AND USES THEREOF
US6995254B1 (en) 1996-08-28 2006-02-07 Affinium Pharmaceuticals, Inc. Polynucleotide encoding the enoyl-acyl carrier protein reductase of Staphylococcus aureus, FAB I
US20050112713A1 (en) * 1996-08-28 2005-05-26 Affinium Pharmaceuticals, Inc. Methods of using Fab I and compounds modulating Fab I activity
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
US5859028A (en) * 1997-04-28 1999-01-12 Potomax Limited Partnership Carotenoid synthesis inhibiting herbicides and fatty acid synthesis inhibiting oxime herbicides as anti-Apicomplexa protozoan parasite agents
US6171856B1 (en) 1997-07-30 2001-01-09 Board Of Regents, The University Of Texas System Methods and compositions relating to no-mediated cytotoxicity
US6713654B1 (en) * 1997-08-29 2004-03-30 The Johns Hopkins University School Of Medicine Antimicrobial compounds
AU9036998A (en) * 1997-08-29 1999-03-16 Johns Hopkins University, The Antimicrobial compounds
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
AR024158A1 (es) 1999-06-01 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
US7279007B2 (en) * 1999-08-09 2007-10-09 Cardioklnetix, Inc. Method for improving cardiac function
EP1206463A4 (en) * 1999-08-23 2003-01-29 Smithkline Beecham Corp FATTY ACID SYNTHASE INHIBITORS
US6730684B1 (en) 1999-10-08 2004-05-04 Affinium Pharmaceuticals, Inc. Fab I inhibitors
ES2231275T3 (es) 1999-10-08 2005-05-16 Affinium Pharmaceuticals, Inc. Inhibidores de fab i.
US6762201B1 (en) 1999-10-08 2004-07-13 Affinium Pharmaceuticals, Inc. Fab I inhibitors
US6951729B1 (en) 1999-10-27 2005-10-04 Affinium Pharmaceuticals, Inc. High throughput screening method for biological agents affecting fatty acid biosynthesis
WO2001030988A1 (en) * 1999-10-27 2001-05-03 Smithkline Beecham Corporation Methods for making and using fatty acid synthesis pathway reagents
US6656703B1 (en) * 1999-12-29 2003-12-02 Millennium Pharamaceuticals, Inc. High throughput screen for inhibitors of fatty acid biosynthesis in bacteria
AU2761101A (en) * 2000-01-07 2001-07-24 Virginia Commonwealth University A scintillation proximity assay for type ii fatty acid biosynthetic enzymes
WO2001060174A2 (en) * 2000-02-16 2001-08-23 The Johns Hopkins University School Of Medicine Weight loss induced by reduction in neuropeptide y level
US20040157918A1 (en) * 2001-02-16 2004-08-12 Loftus Thomas M. Weight loss induced by reduction in neuropeptide y level
AU2001247755A1 (en) * 2000-03-23 2001-10-03 Millennium Pharmaceuticals, Inc. High throughput screening for inhibitors of fatty acid, ergosterol, sphingolipid, or phospholipid synthesis in fungi
US7048926B2 (en) * 2000-10-06 2006-05-23 Affinium Pharmaceuticals, Inc. Methods of agonizing and antagonizing FabK
JP4387804B2 (ja) * 2001-04-06 2009-12-24 アフィニアム・ファーマシューティカルズ・インコーポレイテッド ＦａｂＩ阻害剤
US7348023B2 (en) * 2001-11-21 2008-03-25 Kimberly-Clark Worldwide, Inc. Absorbent articles containing additives
US7323186B2 (en) * 2001-11-21 2008-01-29 Kimberly-Clark Worldwide, Inc. Non-absorbent articles containing additives
US6821999B2 (en) * 2001-11-21 2004-11-23 Kimberly-Clark Worldwide, Inc. Methods for inhibiting the production of TSST-1
US6955890B2 (en) * 2002-02-14 2005-10-18 Pyro Pharmaceuticals, Inc. Method for the identification and treatment of pathogenic microorganisms infections by inhibiting one or more enzymes in an essential metabolic pathway
US20060063224A1 (en) * 2002-05-10 2006-03-23 Schechter Alan M Method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in an essential metabolic pathway
US7649012B2 (en) * 2002-07-09 2010-01-19 Fasgen, Inc. Compounds, pharmaceutical compositions containing same, and methods of use for same
PT1575951E (pt) * 2002-12-06 2014-09-15 Debiopharm Int Sa Compostos heterocíclicos, métodos para os preparar e sua utilização em terapia
EP1608377B1 (en) 2003-03-17 2008-10-01 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
EP1648928A2 (en) * 2003-07-11 2006-04-26 Affinium Pharmaceuticals, Inc. Novel purified polypeptides from staphylococcus aureus
CN101022792A (zh) * 2004-05-26 2007-08-22 法斯根有限责任公司 新化合物、包含该化合物的药物组合物及该化合物的应用方法
US8450307B2 (en) * 2004-06-04 2013-05-28 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
US20090156578A1 (en) * 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
EP1991213A2 (en) * 2006-02-08 2008-11-19 Fasgen, Inc. Anti-mycobacterial formulation comprising octanesulphonylacetamide (osa), nonanesulphonylacetamide (nsa) and decanesulphonylacetamide (dsa)
EP2054422B1 (en) * 2006-07-20 2017-06-14 Debiopharm International SA Acrylamide derivatives as fab i inhibitors
WO2008098374A1 (en) 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
WO2009023059A2 (en) 2007-06-01 2009-02-19 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
WO2010118324A2 (en) 2009-04-09 2010-10-14 Nuclea Biotechnologies, LLC Antibodies against fatty acid synthase
EP2861608B8 (en) 2012-06-19 2019-06-19 Debiopharm International SA Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
BR102012033811A8 (pt) * 2012-12-28 2019-12-24 Uniao Brasileira De Educacao E Assistencia Mantenedora Da Puc Rs compostos, uso, composição farmacêutica inibidora de redutase em microorganismos, ligante de inha, e, método para obtenção de ligantes de inha
BR102013006007A2 (pt) * 2013-03-13 2014-11-11 Ubea Compostos, uso, composição farmacêutica inibidora de redutase em microorganismos, ligante de inha, e, método para obtenção de ligantes de inha a partir de derivados de acetamida, ureia, fenol e carboxamida
DK3419628T3 (da) 2016-02-26 2021-01-11 Debiopharm Int Sa Medikament til behandling af diabetiske fodinfektioner
US20210290629A1 (en) * 2016-07-07 2021-09-23 Forschungzentrum Borstel Leibniz-Zentrum fuer Medizin und Biowissenschaften Acc inhibitors for use in treating mycobacterial diseases
EP3266454A1 (en) * 2016-07-07 2018-01-10 Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften Acc inhibitors for use in treating mycobacterial diseases
WO2018170316A1 (en) * 2017-03-16 2018-09-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of identifying myc-driven and lipogenesis-dependent neoplasms and methods of treating the same
ES2944535T3 (es) 2019-02-14 2023-06-22 Debiopharm Int Sa Formulación de afabicina, método para preparar la misma
UA129222C2 (uk) 2019-06-14 2025-02-12 Дебіофарм Інтернешнл С.А. Лікарський засіб і його застосування для лікування бактеріальних інфекцій, пов'язаних з біоплівкою

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE252616C (de) * 1912-01-25 1912-10-23 Gebr Lesser Ablegerad für Kartoffelerntemaschinen mit einem quer zur Fahrrichtung de Maschine umlaufenden Wurfrad
US3630846A (en) * 1967-09-01 1971-12-28 Kitasato Inst And Toyo Jozo Kk Antibiotic production using streptomyces kitasatoensis
US3535309A (en) * 1967-09-01 1970-10-20 Kitasato Inst Antibiotics and their production
US3909361A (en) * 1971-06-29 1975-09-30 Nihon Tokushu Noyaku Seizo Kk Novel antifungal antibiotic substance, process for production of the same, and agricultural and horticultural fungicidal composition containing said substance
JPS5619344B2 (es) * 1972-11-11 1981-05-07
US4110351A (en) * 1973-04-02 1978-08-29 Richardson-Merrell Inc. Hypolipidemic agents RO- or RS- substituted furoic acids, esters and salts
US4011334A (en) * 1975-10-03 1977-03-08 Richardson-Merrell Inc. Use of substituted furan and thiophene carboxaldehydes as hypolipidemic agents
US4738984A (en) * 1973-04-02 1988-04-19 Merrell Dow Pharmaceuticals Inc. Antirhinovirus agents
US4000164A (en) * 1973-04-02 1976-12-28 Richardson-Merrell Inc. Hypolipidemic agents
US4602099A (en) * 1973-04-02 1986-07-22 Merrell Dow Pharmaceuticals Inc. Antirhinovirus agents
US4032647A (en) * 1975-06-16 1977-06-28 Richardson-Merrell Inc. Substituted thenoylacetic acid and esters
US4328246A (en) * 1979-08-14 1982-05-04 Joseph Gold Anti Walker 256 carcinoma agent and combination thereof
JPS59225115A (ja) * 1983-06-06 1984-12-18 Ota Seiyaku Kk 青魚類から得た長鎖高度不飽和脂肪酸を含有する微細カプセル
JPS6058917A (ja) * 1983-09-09 1985-04-05 Rikagaku Kenkyusho 制癌剤
FR2552879B1 (fr) * 1983-10-03 1987-08-14 Pasteur Institut Procede et reactifs pour la detection d'une anomalie genetique dans une matiere biologique, notamment dans une preparation de leucocytes
CA1256372A (en) * 1985-04-11 1989-06-27 Koichiro Miyazima Process for producing liposome composition
US5110731A (en) * 1985-08-26 1992-05-05 Amgen, Inc. System for biotin synthesis
US4789630A (en) * 1985-10-04 1988-12-06 Cetus Corporation Ionic compounds containing the cationic meriquinone of a benzidine
GB8607137D0 (en) * 1986-03-21 1986-04-30 Efamol Ltd Compositions
US5188830A (en) * 1987-03-27 1993-02-23 Merck & Co., Inc. Methods for thrombolytic therapy
US5185149A (en) * 1987-03-27 1993-02-09 Merck & Co., Inc. Methods for thrombolytic therapy
US4968494A (en) * 1987-03-27 1990-11-06 Merck & Co., Inc. Methods and compositions for thrombolytic therapy
JPH01132542A (ja) * 1987-11-19 1989-05-25 Toomen:Kk ゴッシポールラセミ体の光学分割法
US4877782A (en) * 1988-02-16 1989-10-31 The Upjohn Company Zinc ceftiofur complexes
JPH02113850A (ja) * 1988-10-21 1990-04-26 Nippon Oil & Fats Co Ltd 発癌抑制用油脂組成物
US5190969A (en) * 1988-12-20 1993-03-02 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services 2,3-epoxy derivatives as anti retrovital chemotherapeutic agents
AU621434B2 (en) * 1988-12-21 1992-03-12 Merrell Dow Pharmaceuticals Inc. Antiretroviral furan ketones
JPH02247125A (ja) * 1989-03-17 1990-10-02 Koken Kk 悪性腫瘍細胞増殖抑制剤
US5143907A (en) * 1991-05-10 1992-09-01 Boron Biologicals, Inc. Phosphite-borane compounds, and method of making and using the same
US6001644A (en) * 1991-12-17 1999-12-14 The Regents Of The University Of California Mammalian transformation complex comprising a lipid carrier and DNA encoding CFTR
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
ES2183815T3 (es) * 1992-07-24 2003-04-01 Univ Johns Hopkins Quimioterapia para el cancer.
US5539132A (en) * 1994-01-24 1996-07-23 Johns Hopkins University Cerulenin compounds for fatty acid synthesis inhibition

Also Published As

Publication number Publication date
PT738107E (pt) 2003-01-31
DE69528039D1 (de) 2002-10-10
JPH09508370A (ja) 1997-08-26
AU703272B2 (en) 1999-03-25
US5614551A (en) 1997-03-25
ATE223215T1 (de) 2002-09-15
KR100395601B1 (ko) 2003-11-17
WO1995019706A1 (en) 1995-07-27
EP0738107A1 (en) 1996-10-23
DE69528039T2 (de) 2003-08-07
CA2181031A1 (en) 1995-07-27
MX9602934A (es) 1997-12-31
AU1726895A (en) 1995-08-08
DK0738107T3 (da) 2003-01-06
EP0738107B1 (en) 2002-09-04
EP0738107A4 (en) 1998-09-09

Similar Documents

Publication Publication Date Title
DK0738107T3 (da) Inhibitorer for fedtsyresyntese som antimikrobielle midler
ES2161290T3 (es) Derivados de quinazolina.
MX9706345A (es) Compuestos que contienen benzopiran y metodo para su uso.
UY27154A1 (es) Pirimidinas inhibidoras de metaloproteinasa de matriz
CR6726A (es) Compuestos azapoliciclicos condensados con arilo
PY0224080A (es) Alquinos como inhibidores de metaloproteinasa de matriz
UY26782A1 (es) Derivados del benzotiazol
ECSP066855A (es) Derivados de benceno sustituidos por glucopiranosilo, medicamentos que contienen esos compuestos, su aplicación y procedimiento para su preparación
UY27159A1 (es) Inhibidores de metalloproteinasas de matriz basados en pirimidinas fusionadas
AR018719A1 (es) Inhibidores de renina.
HN2002000025A (es) Inhibidores de piridina de metaloproteinasas de la matriz
PA8478501A1 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa
CO4770978A1 (es) Empleo de epinastina para el tratamiento de dolores
ES2183815T3 (es) Quimioterapia para el cancer.
PA8748101A1 (es) Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus
DK0939627T3 (da) Pentaflourbenzensulfonamider og analoger
ES2131973T3 (es) Empleo de 2-amino-4-(4-fluorobencilamino)-1-etoxicarbonilaminobencenos para la profilaxis y el tratamiento de las secuelas de la disminucion aguda y cronica del riego sanguineo cerebral, asi como de afecciones neurodegenerativas.
AR001790A1 (es) Formulaciones para parches transdermicos que sirven para el tratamiento de condiciones modeladas de receptores muscarinicos
UY26951A1 (es) Derivados de ácido propiónico
ES2177849T3 (es) Preparado farmaceutico, que contiene 2-fenil-1,2-benzoisoselenazol-3(2h)-ona, para el tratamiento de la enfermedad de alzheimer.
MX9606494A (es) Compuestos organicos.
ES2180783T3 (es) Composiciones farmaceuticas para el tratamiento de la adiccion al alcohol.
ECSP034635A (es) Uso de compuestos del 1-fenil-3-dimetilaminopropano para el tratamiento de la incontinencia urinaria
PA8531601A1 (es) Nuevos heteroaromatos
UY27324A1 (es) Nuevas sales de napsilato i